VistaGen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2017, the first quarter of fiscal 2018. The company is a clinical-stage biopharmaceutical developer with no commercial products or recurring revenue.
Financial performance and liquidity
- Revenue: $0 in both the 2017 and 2016 quarters. The $1.25 million BlueRock sublicense revenue was recorded in the prior quarter, not this period.
- Operating expenses: $2.261 million, up 15% from $1.963 million. Research and development rose 33% to $1.096 million; general and administrative expense increased 2% to $1.164 million.
- Losses: Operating loss was $2.261 million and net loss was $2.265 million, versus $1.963 million and $1.967 million, respectively, a year earlier. Net loss attributable to common stockholders was $2.513 million, or $0.28 per share, compared with $2.618 million, or $0.51 per share. The per-share comparison reflects a higher weighted-average share count in 2017.
- Cash flow: Cash used in operations was $2.134 million, versus $1.671 million in the prior-year quarter. Financing provided $841,000, principally from equity sales; cash declined $1.293 million to $1.628 million. Investing cash flow was zero.
- Liquidity and debt: Current assets were $2.126 million and current liabilities $1.005 million, giving working capital of about $1.121 million. Total liabilities were $3.044 million. Current notes payable and accrued interest were $165,500; capital lease obligations totaled $13,700. Accrued Series B preferred dividends were $1.825 million.
- Equity: Stockholders’ deficit was $607,000, versus positive equity of $616,000 at March 31, 2017. Accumulated deficit was $144.3 million. Gross margin is not meaningful because the company reported no revenue.
Changes from the comparable period
- Net loss increased by about $298,000, primarily alongside higher R&D spending, partly offset in the common-stockholder loss measure by lower Series B dividend accruals and no deemed dividend in 2017.
- Operating cash use increased by $463,000. Financing proceeds fell sharply from $9.744 million in the 2016 quarter to $841,000 in 2017, when the company raised about $1.0 million in a self-placed private placement.
- Noncash stock-based compensation increased to $367,000 from $108,000.
Outlook, risks and other notable items
- Management estimated approximately $12 million of cash expenditures for the 12 months following issuance of the financial statements. June 30 cash, including subsequent financing proceeds, was insufficient to fund planned operations for that period. The filing states that this raises substantial doubt about the company’s ability to continue as a going concern without additional financing.
- Management planned to seek additional capital, primarily through equity offerings, and noted an effective Form S-3 registration statement, but had not sold securities under it as of the report date. A proposed increase in authorized common shares from 30 million to 100 million required stockholder approval. Financing may be unavailable, dilutive, delayed, or on unacceptable terms.
- The company was preparing a 180-patient Phase 2 adjunctive MDD study of AV-101. Management anticipated launch in the first quarter of 2018, completion by year-end 2018, and top-line results in the first quarter of 2019, all subject to adequate financing. The NIMH-funded Phase 2 monotherapy study was expected to finish by year-end 2017, with results in the first half of 2018.
- Key risks include clinical efficacy and safety uncertainty, regulatory and manufacturing delays, reliance on third-party CROs and manufacturers, competition, and dependence on external funding. The filing says AV-101 had not yet completed a Phase 2 trial and notes that approval, if achieved, was unlikely before at least 2021.
- The company reported no legal proceedings and no off-balance-sheet arrangements. Disclosure controls were deemed effective, but two previously identified material weaknesses in financial reporting controls—segregation of duties and accounting-software functionality—remained unremediated.
Important facts for investors to verify
- Whether the company raised sufficient financing after the filing to fund operations and the planned AV-101 study, and how long available cash supports operations.
- Whether stockholders approved the proposed increase in authorized common shares, and the resulting actual and potential dilution from shares, preferred stock, options, and warrants.
- Whether AV-101 study enrollment, launch, completion, and results timelines remain achievable, and what the NIMH monotherapy study ultimately showed.
- Whether management has remediated the disclosed internal-control material weaknesses and whether future filings report any changes.